Delisting riskPopularity #4,827
Biomerica (BMRA)
Makes rapid diagnostic tests and GI-focused laboratory assays for clinical and consumer use.
$2.59
vs last close−0.19 (−6.83%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 4.05% | 125.2K shares | |
|---|---|---|---|
| 20 holders · as of Jun 30, 2026 | |||
| Insiders | 17.53% | 541.7K shares | |
| 8 holders · as of Aug 27, 2026 | |||
| Strategic holders | 14.89% | 460.1K shares | |
| 1 holder · as of Sep 10, 2026 | |||
| Other | 63.53% | 1.96M shares | |
| remainder | |||
3.09M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
20 holders · 125.2K shares · 9 new positions · 10 increased · 2 reduced · 0 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| HRT Financial LP | 26.4K | 0.85% | +26.4Knew | Aug 14, 2026 |
| Geode Capital Management, LLC | 24.3K | 0.79% | −31.7K | Aug 12, 2026 |
| BlackRock, Inc. | 18.6K | 0.60% | 0 | Aug 7, 2026 |
| Vanguard Capital Management LLC | 14.5K | 0.47% | 0 | Aug 13, 2026 |
| Jane Street Group, LLC | 12.6K | 0.41% | +12.6Knew | Aug 14, 2026 |
| LPL Financial LLC | 10.8K | 0.35% | 0 | Aug 7, 2026 |
| UBS Group AG | 7.0K | 0.22% | +6.4K | Aug 13, 2026 |
| Vanguard Fiduciary Trust Co | 6.6K | 0.21% | 0 | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| B. Riley Principal Capital, LLCincl. Bryant R. Riley, BRC Group Holdings, Inc. | 10.03% | 460.1K | 13D | Aug 28, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 26, 2026 | Allen Barbieridirector, officer: Executive Vice Chairman | Purchase | 20,000 | $1.60 | 73,542 |
| Aug 26, 2026 | Eric Chindirector | Purchase | 6,250 | $1.60 | 38,750 |
| Aug 26, 2026 | David Moatazedidirector | Purchase | 10,000 | $1.60 | 40,625 |
| Aug 20, 2026 | M. Huff Garydirector | Purchase | 31,250 | $1.60 | 51,250 |
| Aug 26, 2026 | Zackary S. Iranidirector, officer: Chief Executive Officer | Purchase | 31,250 | $1.60 | 242,570 |
House and Senate disclosures
Not reported.